Search results for " vivo"

showing 10 items of 1661 documents

Antigen specificity and clinical significance of IgG and IgA autoantibodies produced in situby tumor-infiltrating b cells in breast cancer

2018

An important role for tumor infiltrating B lymphocytes (TIL-B) in the immune response to cancer is emerging; however, very little is known about the antigen specificity of antibodies produced in situ. The presence of IgA antibodies in the tumor microenvironment has been noted although their biological functions and clinical significance are unknown. This study used a 91-antigen microarray to examine the IgG and IgA autoantibody repertoires in breast cancer (BC). Tumor and adjacent breast tissue supernatants and plasma from BC patients together with normal breast tissue supernatants and plasma from healthy controls (patients undergoing mammary reduction and healthy blood donors) were analyze…

0301 basic medicinelcsh:Immunologic diseases. AllergyAdultMaleautoantibodiesIgGT cellImmunologytumor-infiltrating B cellsBreast Neoplasms03 medical and health sciences0302 clinical medicineImmune systemLymphocytes Tumor-Infiltratingbreast cancerAntigenAntibody SpecificityAntigens NeoplasmImmunology and AllergyMedicineHumansAgedOriginal ResearchTumor microenvironmentB-Lymphocytesbiologybusiness.industryAutoantibodyGerminal centerGénéralitésMiddle AgedImmunoglobulin A030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisImmunoglobulin GImmunologybiology.proteinFemaleAntibodybusinesslcsh:RC581-607Ex vivoIgAtertiary lymphoid structures
researchProduct

Characterization of zolbetuximab in pancreatic cancer models

2018

ABSTRACT In healthy tissue, the tight junction protein Claudin 18.2 (CLDN18.2) is present only in the gastric mucosa. Upon malignant transformation of gastric epithelial tissue, perturbations in cell polarity lead to cell surface exposure of CLDN18.2 epitopes. Moreover, CLDN18.2 is aberrantly expressed in malignancies of several other organs, such as pancreatic cancer (PC). A monoclonal antibody, zolbetuximab (formerly known as IMAB362), has been generated against CLDN18.2. In a phase 2 clinical trial (FAST: NCT01630083), zolbetuximab in conjunction with chemotherapy prolonged overall and progression-free survival over chemotherapy alone and improved quality of life. In this study, the mech…

0301 basic medicinelcsh:Immunologic diseases. AllergyImmunologyCellclaudin 18.2pancreatic cancerlcsh:RC254-282Malignant transformation03 medical and health sciences0302 clinical medicinePancreatic cancermedicineImmunology and AllergyCytotoxicitycomplement-dependent cytotoxicityOriginal ResearchAntibody-dependent cell-mediated cytotoxicityChemistryimab362medicine.diseasetargeted therapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensComplement-dependent cytotoxicity030104 developmental biologymedicine.anatomical_structureOncologyadccCell culturemonoclonal antibody030220 oncology & carcinogenesisCancer researchimmunotherapyzolbetuximablcsh:RC581-607Ex vivoantibody-dependent cellular cytotoxicityOncoImmunology
researchProduct

The Protein Corona as a Confounding Variable of Nanoparticle-Mediated Targeted Vaccine Delivery

2018

Nanocarriers (NC) are very promising tools for cancer immunotherapy. Whereas conventional vaccines are based on the administration of an antigen and an adjuvant in an independent fashion, nanovaccines can facilitate cell-specific co-delivery of antigen and adjuvant. Furthermore, nanovaccines can be decorated on their surface with molecules that facilitate target-specific antigen delivery to certain antigen-presenting cell types or tumor cells. However, the target cell-specific uptake of nanovaccines is highly dependent on the modifications of the nanocarrier itself. One of these is the formation of a protein corona around NC after in vivo administration, which may potently affect cell-speci…

0301 basic medicinelcsh:Immunologic diseases. AllergyMini Reviewmedicine.medical_treatmentImmunologyCellcell-specific targetingProtein Corona02 engineering and technology03 medical and health sciencesprotein coronaAntigenCancer immunotherapyIn vivoNeoplasmsmedicineHumansImmunology and AllergyReceptors ImmunologicnanocarriersChemistryImmunotherapy021001 nanoscience & nanotechnologyBody FluidsTreatment Outcome030104 developmental biologymedicine.anatomical_structureCancer researchNanoparticlesimmunotherapyNanocarriers0210 nano-technologylcsh:RC581-607Adjuvantcancer vaccinesProtein BindingFrontiers in Immunology
researchProduct

Characterization of EGF-guided MDA-MB-231 cell chemotaxis in vitro using a physiological and highly sensitive assay system

2018

Chemotactic cell migration is a central mechanism during cancer cell invasion and hence metastasis. In order to mimic in vivo conditions, we used a three-dimensional hydrogel matrix made of collagen I and a stable gradient-generating chemotaxis assay system, which is commercially available (μ-Slide Chemotaxis) to characterize epidermal growth factor (EGF)-induced chemotaxis of the human breast cancer cell line MDA-MB-231. Surprisingly, chemotactic effects of EGF on MDA-MB-231 cells could neither be observed in the standard growth medium DMEM/F-12 supplemented with 10% serum nor in starvation medium. In contrast, after adapting the cells to the serum-free growth medium UltraCULTURETM, signif…

0301 basic medicinelcsh:MedicineBreast Neoplasms03 medical and health sciences0302 clinical medicineEpidermal growth factorIn vivoCell Line TumorHumansNeoplasm Metastasislcsh:ScienceReceptorMultidisciplinaryEpidermal Growth FactorTissue ScaffoldsChemistryChemotaxislcsh:RHydrogelsCell migrationChemotaxisPeptide FragmentsCulture MediaCell biologyErbB Receptors030104 developmental biologyCell culture030220 oncology & carcinogenesisCancer celllcsh:QCollagenChemotaxis assayPLOS ONE
researchProduct

Dynamics of a Protein Interaction Network Associated to the Aggregation of polyQ-Expanded Ataxin-1

2020

Background: Several experimental models of polyglutamine (polyQ) diseases have been previously developed that are useful for studying disease progression in the primarily affected central nervous system. However, there is a missing link between cellular and animal models that would indicate the molecular defects occurring in neurons and are responsible for the disease phenotype in vivo. Methods: Here, we used a computational approach to identify dysregulated pathways shared by an in vitro and an in vivo model of ATXN1(Q82) protein aggregation, the mutant protein that causes the neurodegenerative polyQ disease spinocerebellar ataxia type-1 (SCA1). Results: A set of common dysregulated pathwa…

0301 basic medicinelcsh:QH426-470Ataxin 1Mice TransgenicNerve Tissue ProteinsProtein aggregationBlood–brain barrierblood-brain-barrierArticledrugspolyQ03 medical and health sciences0302 clinical medicineataxin-1Interaction networkIn vivoMutant proteinCerebellumGeneticsmedicineAnimalsGene Regulatory NetworksProtein Interaction MapsGenetics (clinical)NeuronsbiologypathwayGene Expression Profilingmedicine.diseaselcsh:Genetics030104 developmental biologymedicine.anatomical_structureGene Expression Regulationnetworkbiology.proteinSpinocerebellar ataxiaPeptidesNeuroscience030217 neurology & neurosurgeryFunction (biology)Genes
researchProduct

MARTX Toxin in the Zoonotic Serovar of Vibrio vulnificus Triggers an Early Cytokine Storm in Mice

2017

Vibrio vulnificus biotype 2-serovar E is a zoonotic clonal complex that can cause death by sepsis in humans and fish. Unlike other biotypes, Bt2 produces a unique type of MARTXVv (Multifunctional-Autoprocessive-Repeats-in-Toxin; RtxA13), which is encoded by a gene duplicated in the pVvBt2 plasmid and chromosome II. In this work, we analyzed the activity of this toxin and its role in human sepsis by performing in vitro, ex vivo, and in vivo assays. First, we demonstrated that the ACD domain, present exclusively in this toxin variant, effectively has an actin-cross-linking activity. Second, we determined that the whole toxin caused death of human endotheliocytes and monocytes by lysis and apo…

0301 basic medicinelcsh:QR1-502MicrobiologiaVibrio vulnificusmedicine.disease_causeMonocyteslcsh:MicrobiologysepsisVibrio vulnificusCells CulturedOriginal ResearchMice Inbred BALB CCell DeathVirulencebiologyqPCR arrayInfectious DiseasesHost-Pathogen InteractionsBacteris patògensCytokinesV. vulnificusFemaleMicrobiology (medical)Virulence FactorsBacterial ToxinsImmunologyVirulenceSerogroupMicrobiologyMicrobiology03 medical and health sciencesImmune systemMARTXIn vivomedicineAnimalsHumansVibrioToxinEndothelial Cellsbiology.organism_classificationmedicine.diseaseVirologyVibrioinfectionDisease Models Animal030104 developmental biologyInfecciógene expressionCytokine stormEx vivoFrontiers in Cellular and Infection Microbiology
researchProduct

Use of Ganoderma lucidum (Ganodermataceae, Basidiomycota) as Radioprotector

2020

For millennia, naturopaths and physicians have used Ganoderma lucidum (reishi mushroom) for its diverse therapeutic properties, as recorded in the oldest Chinese herbal encyclopedia. Indeed, a radioprotective effect has been reported in the isolated components of its extracts. A systematic review and meta-analyses (PRISMA) was conducted in March 2020, searching databases including PubMed, Scopus, Embase, and Google Scholar, along with Clinical Trials. The inclusion criteria were ex vivo, in vitro, and in vivo studies, with full texts in English, conducted to determine the radioprotective benefits of G. lucidum, or reports in which ionizing radiation was used. From a total number of 1109 rec…

0301 basic medicinelcsh:TX341-641Ganoderma lucidumBiology03 medical and health sciences0302 clinical medicineIn vivoradioprotectorGanoderma lucidumMushroomGanodermataceaeNutrition and DieteticsTraditional medicinein vitroBasidiomycotabiology.organism_classificationIn vitroClinical trialin vivo030104 developmental biology030220 oncology & carcinogenesisex vivoreishi mushroomlcsh:Nutrition. Foods and food supplyEx vivoFood ScienceNutrients
researchProduct

Effect of plant sterol and galactooligosaccharides enriched beverages on oxidative stress and longevity in Caenorhabditis elegans

2020

Abstract This study evaluates the impact of two plant sterol (PS) enriched fruit beverages (0.6 g /100 ml), without (MfB) or with GOS (MfB-G) (1.2 g/100 ml) on the resistance against oxidative stress induced by non-conventional (cholesterol oxidation products (COPs)) and conventional (H2O2) oxidant compounds, as well as their impact on C. elegans longevity. Nematodes fed with both beverages (0.005–0.25%, v/v) showed similar improved oxidative stress resistance against COPs and H2O2. This effect was dependent on daf-16 transcription factor, although GOS showed an additional beneficial effect independent to daf-16. In addition, both beverages extended nematode lifespan, independently of the p…

0301 basic medicinemedia_common.quotation_subjectMutantCholesterol oxidation productsMedicine (miscellaneous)Milk-based fruit beveragesmedicine.disease_causePlant sterols03 medical and health scienceschemistry.chemical_compound0404 agricultural biotechnologyIn vivomedicineTX341-641Caenorhabditis elegansTranscription factorCaenorhabditis elegansmedia_common030109 nutrition & dieteticsNutrition and DieteticsbiologyCholesterolNutrition. Foods and food supplyLongevity04 agricultural and veterinary sciencesbiology.organism_classification040401 food scienceNematodechemistryBiochemistryOxidative stressFood ScienceGalactooligosaccharidesJournal of Functional Foods
researchProduct

A new class of phenylhydrazinylidene derivatives as inhibitors of Staphylococcus aureus biofilm formation

2016

In the struggle against the emergence of the antibiotic resistance, new molecules targeting biofilm formation could be useful as adjuvant of conventional antibiotics. This study focused on a new class of 2-phenylhydrazinylidene derivatives as antivirulence agents. The compound 12e showed interesting activities against biofilm formation of all tested Staphylococcus aureus strains with IC50 ranging from 1.7 to 43 µM; compounds 12f and 13a resulted strong inhibitors of S. aureus ATCC 6538 and ATCC 29213 biofilm formation with IC50 of 0.9 and 0.8 µM, respectively. A preliminary study on the mechanism of action was carried on evaluating the inhibition of sortase A transpeptidase. Compound 12e re…

0301 basic medicinemedicine.drug_class030106 microbiologyAntibioticsBacterial adhesionAntibiofilm agentSettore BIO/19 - Microbiologia Generalemedicine.disease_causeMicrobiologyAntivirulence agent03 medical and health sciencesAntibiotic resistanceIn vivomedicineGeneral Pharmacology Toxicology and PharmaceuticsbiologyChemistrySortase AOrganic ChemistryBiofilmPhenylhydrazinylidene derivativebiochemical phenomena metabolism and nutritionbiology.organism_classificationSettore CHIM/08 - Chimica FarmaceuticaGalleria mellonellaSettore AGR/11 - Entomologia Generale E Applicata030104 developmental biologyMechanism of actionBiochemistryStaphylococcus aureusPharmacology Toxicology and Pharmaceutics (all)Sortase Amedicine.symptomMedicinal Chemistry Research
researchProduct

Caenorhabditis elegans as an in vivo model to assess fucoidan bioactivity preventing Helicobacter pylori infection

2020

Currently, Helicobacter pylori is the unique biological carcinogenic agent. The search for antimicrobial alternatives to antibiotics against this pathogen has been categorized as a priority due to the drastic failure associated with current applied antibiotic therapy. The present study assessed the bioactive antimicrobial capability of fucoidan (“Generally Recognized as Safe” approval – European Commission December 2017) from different species of Phaeophyceae algae (Fucus vesiculosus, Undaria pinnatifida, Macrocystis pyrifera) against H. pylori. All the studied fucoidans showed bacteriostatic and bactericidal effects at the studied concentrations [5–100] μg ml−1 and exposure times [0–7 days…

0301 basic medicinemedicine.drug_classAntibioticsPhaeophytaMicrobiologyHelicobacter Infections03 medical and health scienceschemistry.chemical_compound0302 clinical medicineNutraceuticalAnti-Infective AgentsIn vivoPolysaccharidesGenerally recognized as safemedicineAnimalsCaenorhabditis elegansPathogenbiologyHelicobacter pyloriFucoidanGeneral MedicineHelicobacter pyloribiology.organism_classificationAntimicrobial3. Good healthDisease Models Animal030104 developmental biologychemistry030220 oncology & carcinogenesisFood Science
researchProduct